<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220908055916N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-01-19</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Nano Propolis in Donor Site Graft Healing</public_title>
      <acronym></acronym>
      <scientific_title>Determination and Comparision the Effectiveness of Nano Propolis in Wound healing of the donor site Skin Graft in Patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67764</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Education/Guidance, Randomization description: Randomization is not done to select People because the Case and Control are done on One Person, but Randomization is done for the Type of Cream in the Wound Healing Site. The Lesions on the Patient's Body will be randomly selected based on the Block Classification of Four Numbers prepared by Excel Software, and will be placed in One of the Two relevant Groups to receive the Panemsan Type, Blinding description: In Order to blind the Patient and not know which Cream was used in which Area, the Blinding will be done in a (double-blind) way, so that the Patient will be given Two Gels in the same Tubes. It is given and asked from the Patient that It is the Supervisor Who knows which Lesion of the Patient with which Code, which Gel will be prescribed with which Code, and the Researcher and the Patient do not know about the Codes related to the Lesions and the Content of the Gels.
Randomly, in One of the Two Skin Graft harvesting Sites, Treatment with Nano Propolis gel (Group A) and Placebo Treatment (base Gel without Propolis - Group B) will be used in the Other Place. Nanopropolis Gel and Placebo Gel are similar in Appearance, Weight, Color and Consistency and can only be recognized by a Special Code that was prepared by the harmaceutical Company in cooperation with Sharif University and with the Formulation that is available in the Attachment, and the Researcher and the Patient They do not know about the Codes related to the Content of the Gels.
The Random Selection Sequence of Groups A and B will be calculated by a Statistician and Methodology Expert and maintained by a Person Who has no Other Interest or Participation in the Project. The Researchers and Subjects and the Statistical Analyst will be blind to the Content of the Gels throughout the Study and during the statistical Analysis.</study_design>
      <phase>3</phase>
      <hc_freetext>patients need skin graft.</hc_freetext>
      <i_freetext>Intervention 1: patients with skin defects candidated healing with partial thicknes skin grafts  after harvesting the grafted skin at the donor site, which are divided into two equal parts with a distance, and each of these parts are selected as intervention and control subjects:                                                        intervention group: in the part that is randomly assigned to The place of intervention is selected, honey nano propolis ointment is prescribed, and after training, daily dressing is done, and on days 1-3-7-14-21-28, the condition of wound healing is checked using Bates-Jensen criteria. Intervention 2: Control group: Control group: Vaseline ointment is prescribed in the part that is randomly selected as the control area, and after training, dressing is done daily and on days 1-3-7-14-21-28 using criteria bates-jensen tests and wound healing status are examined.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data will be released after de-identification

When:
the access period starts 6 months after the results are published

To whom:
all researchers

Conditions:
By mentioning the source, it is possible to analyze the data

Where to obtain:
Request from the responsible author

How to obtain:
Upon request, the data will be sent by e-mail within one month

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hamed Shahdadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tehran,Keshavarz blvd, Imam Hospital,Plastic department</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1444863841</zip>
        <telephone>+98 21 6119 2472</telephone>
        <email>hamedshahdadi@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hamed Shahdadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tehran,Keshavarz blvd,Imam Hospital, Plastic department</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1444863841</zip>
        <telephone>+98 21 6119 2472</telephone>
        <email>hamedshahdadi@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients Schaduled for partial Thickness Skin Graft with informed Consent</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>history of graft harvest from donor site
history of kelloid and HTS
Cigarette smoking
allergy history to honey
history of wound healing impairment disorder
old age patient(&gt;60 years old)
immune deficient patient
pregnant patient
with out informed consent</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>t14.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Superficial injury of unspecified body region</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>patients with skin defects candidated healing with partial thicknes skin grafts  after harvesting the grafted skin at the donor site, which are divided into two equal parts with a distance, and each of these parts are selected as intervention and control subjects:                                                        intervention group: in the part that is randomly assigned to The place of intervention is selected, honey nano propolis ointment is prescribed, and after training, daily dressing is done, and on days 1-3-7-14-21-28, the condition of wound healing is checked using Bates-Jensen criteria.</i_keyword>
      <i_keyword>Control group: Control group: Vaseline ointment is prescribed in the part that is randomly selected as the control area, and after training, dressing is done daily and on days 1-3-7-14-21-28 using criteria bates-jensen tests and wound healing status are examined.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Wound healing according to bates-jensen criteria. Timepoint: 1-3-7-14-21-28 day. Method of measurement: bates-jensen scoring.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Wound infection rate. Timepoint: 1-3-7-14-21-28 day. Method of measurement: examination or culture.</sec_outcome>
      <sec_outcome>Pain. Timepoint: 1-3-7-14-21-28 day. Method of measurement: visual analogue score.</sec_outcome>
      <sec_outcome>Scar. Timepoint: 1-3-7-14-21-28 day. Method of measurement: physical exam.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-12-24</approval_date>
        <contact_name>Ethics committee of Imam Khomeini Hospital Tehran University of Medical Sciences</contact_name>
        <contact_address>tehran, keshavarz blvd,imam khumeini hospital تهران Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
